Delay of Generics Hurts Consumer,
Taxpayer Wallets, and Patient Health

Tweet   To insure patent extensions of high-priced, blockbuster drugs, brand-name drug companies frequently pay generic drug manufacturers to stay out of the market. It makes cheaper, more affordable generic unavailable for years. The strategy is referred to as “Pay for Delay.” The Federal Trade Commission has lots of information on this problem and its